Med. praxi. 2017;14(5):224-229 | DOI: 10.36290/med.2017.043

Do we have reserves in treatment after myocardial infarction?

prof. MUDr. Jindřich ©pinar, CSc., FESC1, prof. MUDr. Lenka ©pinarová, Ph.D., FESC2, prof. MUDr. Jiří Vítovec, CSc., FESC2
1 Interní kardiologická klinika FN Brno a Lékařská fakulta Masarykovy univerzity, Brno
2 Interní kardio-angiologická klinika, FN u sv. Anny a Lékařská fakulta Masarykovy univerzity, Brno

Early reperfusion is the basic treatment of acute coronary syndrome. Regime recommen-dation and pharmacotherapy must followin order to prevent remodelation of left ventricle, restenosis, rethrombosis and arrhythmias. Four basic drug groups are usedrenin angiotensin aldosteron blockers, betablockers, antiagregation and lipid lowering drugs. The use of these drugs in the Czechregistry FARIM was: ACE-inhibitors (ACE-i) or sartans 90 % of patients, betablockers (BB) 86 % and statins 92 %. But the doses werefrequently insufficient. High dose of ACE inhibitors (sartans) and statins received only 25% of the patients.

Keywords: myocardial infarction, pharmacotherapy, doses

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, ©pinarová L, Vítovec J. Do we have reserves in treatment after myocardial infarction? Med. praxi. 2017;14(5):224-229. doi: 10.36290/med.2017.043.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Valgimigli M, Gagnor A, Calabro' P, et al. MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomized multicentre trial. Lancet 2015; 385: 2465-2476. Go to original source... Go to PubMed...
    2. Nussbaumerova B, Rosolova H, Mayer O jr., et al. Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I-IV surveys). Cor et Vasa. 2014; 56: e98-e104. Go to original source...
    3. ©pinar J. Rivaroxaban u pacientů s akutním koronárním syndromem - studie ATLAS ACS 2-TIMI 51. Remedia 2012; 22(2): 154-158.
    4. ©pinar J, Vítovec J. Je farmakoterapie po infarktu dostatečná? Interní medicína pro praxi 2009; 11(2): 84-86.
    5. Vítovec J, ©pinar J. Farmakoterapie po infarktu myokardu. Cor et Vasa 2009; 51(2): 90-91. Go to original source...
    6. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40-47. Go to original source... Go to PubMed...
    7. ©imon J, et al. Epidemiologie a prevence ischemické choroby srdeční. 1. vyd. Praha, Grada Publishing 2001: 264 s.
    8. Roffi M, Patrono C, Collet JP, Mueller C, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315. Go to original source... Go to PubMed...
    9. Amsterdam EA, Wenger NK, Brindis RG, et al. ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: 2354-2394. Go to original source... Go to PubMed...
    10. European Cardiovascular Disease Statistics 2017. Dostupné z: http://www.ehnheart.org/cvd-statistics.htm
    11. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva 2003.
    12. Anand SS, Islam S, Rosengren A, et al. INTERHEART Investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008; 29(7): 932-940. Go to original source... Go to PubMed...
    13. Filipovský J, Widimský J jr., Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-802. Go to PubMed...
    14. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290-300. Go to original source... Go to PubMed...
    15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Journal of Hypertension 2013; 31: 1281-1357. Go to original source... Go to PubMed...
    16. ©pinarová L, ©pinar J, Vítovec J. Farmakoterapie po srdečním infarktu. Vnitřní lékařství 2011; 57(11): 966-970. Go to PubMed...
    17. Vítovec J, ©pinarová L, ©pinar J. Péče o pacienta po infarktu myokardu. Medicína po promoci 2011; 12(6): 89-91.
    18. ONTARGET study investigators: Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    19. Yusuf S for the TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovscular event in high risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183. Go to original source... Go to PubMed...
    20. Savarese G, Costanzo P, Cleland JGF, et al. A Meta-Analysis reparting efects of angiotensin-converting enzyme inhibitors and angiotension receptor blockers in patients without heart failure. JACC 2013. Go to original source...
    21. Vítovec J, ©pinar J. Bradykardizující léky v terapii pacientů po infarktu myokardu. Cor et Vasa 2009; 51(2): 97-102. Go to original source...
    22. Vítovec J, ©pinarová L, ©pinar J. Sekundární prevence po infarktu myokardu - reľimové a farmakologické postupy. Interní medicína pro praxi 2011; 5: 202-204.
    23. Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166. Go to original source... Go to PubMed...
    24. Udell JA, Bonaca MP, Collet JP, et al. Longterm dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2015; [2015-08-31]. Dostupné z: doi:10.1093/eurheartj/ehv443. Go to original source... Go to PubMed...
    25. Heidebuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm AssociaTION Practical Guidelines on the use of non-vitamin K antagonist anticoagulans in patients with non valvular atrial fibrillation: executive summary. Eur Heart J ehw 058 2016. Go to original source... Go to PubMed...
    26. Staněk V. Léčba srdečního infarktu. Cor Vasa 2002; 44: 207-208.
    27. ©paček R, Widimský P. Infarkt myokardu. Galén 2003: 231 s.
    28. Walentin L, Becker R, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndroms. NEJM 2009; 361(12): 1045-1057. Go to original source... Go to PubMed...
    29. Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Commit-tee and Investigators. Long-term use of ticagrelor in patients with prior myo-cardial infarction. N Engl J Med 2015; 372: 1791-1800. Go to original source... Go to PubMed...
    30. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387-2397. Go to original source... Go to PubMed...
    31. Soąka V, Vrablík M, Bláha V, et al. PCSK9 inhibitory: nové moľnosti v léčbě hypercholesterolemie. U koho budou indikovány? Vnitr Lek 2016; 62(4): 329-333. Go to PubMed...
    32. ©pinar J, Vítovec J. Inhibitory ACE nebo sartany v léčbě pacientů po infarktu myokardu? Cor et Vasa 2009; 51(2): 103-111. Go to original source...
    33. ©pinar J, Sepąi M, Ludka O. Registr Brno - Farmakoterapie po infarktu myokardu. Cor et Vasa 2009; 51(2): 128-130. Go to original source...
    34. ©pinar J, Vítovec J, ©pinarová L, v zastoupení řeąitelů studie FARIM. FARIM - FARmakoterapie po Infarktu Myokardu. Vnitřní lékařství 2011; 57(9):778-785. Go to PubMed...
    35. ©pinar J, Vítovec J, a kol. Ischemická choroba srdeční. Grada Publ. 2003: 364 s.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.